Contineum Therapeutics Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
/ 
Others were interested in
See all stocksFrequently asked questions
To buy Contineum Therapeutics Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Contineum Therapeutics Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Contineum Therapeutics Inc. is CTNM:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Contineum Therapeutics Inc. has its primary listing on NASDAQ. You can trade Contineum Therapeutics Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Contineum Therapeutics Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Contineum Therapeutics Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Contineum Therapeutics Inc..